TEZSPIRE Subcutaneous Injection 210mg Specific Use-results Study (Long Term) in Patients with Bronchial Asthma
Latest Information Update: 03 May 2025
At a glance
- Drugs Tezepelumab (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors AstraZeneca
Most Recent Events
- 11 Apr 2023 Status changed from not yet recruiting to recruiting.
- 20 Feb 2023 New trial record